Post-transplant lymphoproliferative disorder (PTLD) encompasses a range of lymphoid proliferations triggered by immunosuppression in organ and stem cell transplant recipients, from benign hyperplasia ...
Please provide your email address to receive an email when new articles are posted on . About half of patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease responded ...
A Prescription Drug User Fee Act target date of January 10, 2026 has been set for the resubmitted application. The Food and Drug Administration (FDA) has accepted for Priority Review the resubmitted ...
—A new study from Switzerland suggests that post-transplant lymphoproliferative disorders (PTLDs) may represent clonal expansions driven by exogenic immunosuppression, Epstein-Barr virus (EBV) ...
Assessment of Response to Induction Therapy and Its Influence on 5-Year Failure-Free Survival in Group III Rhabdomyosarcoma: The Intergroup Rhabdomyosarcoma Study-IV Experience—A Report From the Soft ...
Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin’s Lymphomas A prognostic model has ...
Atara Biotherapeutics received a second complete response letter from the FDA for its biologics license application for Ebvallo (tabelecleucel). The letter, received Jan. 9, said the FDA no longer ...
Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells. The Food and Drug Administration (FDA) has accepted for Priority Review the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results